Giuseppe Navarra

Dr. Giuseppe Navarra


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2002 in Annals of Surgery
Verified
Journal Article
Closed access
JWJean-Christophe Weber
Jean-Christophe Weber
GNGiuseppe Navarra
Giuseppe Navarra
LJLong R. Jiao
Long R. Jiao
JNJoanna P. Nicholls
Joanna P. Nicholls
SJSteen Lindkaer Jensen
Steen Lindkaer Jensen
NHNagy A. Habib
Nagy A. Habib
To assess a new bloodless technique using radiofrequency energy for segmental liver resection of hepatic tumors. Liver resection remains a formidable surgical procedure; safe performance requires a high level of training and skill. Intraoperative blood loss during liver resection remains a major concern because it is associated with a higher rate of postoperative complications and shorter long-term survival. From January 2000 to June 2001, 15 patients with various hepatic tumors were operated on using radiofrequency energy to remove the tumor in its entirety. Radiofrequency energy was applied along the margins of the tumor to create “zones of necrosis” before resection with a scalpel. No blood transfusions were required. The mean blood loss during resection was 30 ± 10 mL. No mortality or morbidity was observed. The median postoperative stay was 8 days (range 5–9). No liver recurrence was detected in patients undergoing resection with this technique during follow-up periods ranging from 2 to 20 months. Segmental and wedge liver resection assisted by radiofrequency is safe. This novel technique offers a new method for transfusion-free resection.

15 April 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PCPaolo Carrega
Paolo Carrega
IBIrene Bonaccorsi
Irene Bonaccorsi
ECEmma Di Carlo
Emma Di Carlo
BMBarbara Morandi
Barbara Morandi
PPPetra Paul
Petra Paul
GFGuido Ferlazzo
Guido Ferlazzo
As limited information is available regarding the distribution and trafficking of NK cells among solid organs, we have analyzed a wide array of tissues derived from different human compartments. NK cells were widely distributed in most solid tissues, although their amount varied significantly depending on the tissue/organ analyzed. Interestingly, the distribution appeared to be subset specific, as some tissues were preferentially populated by CD56brightperforinlow NK cells, with others by the CD56dimperforinhigh cytotoxic counterpart. Nevertheless, most tissues were highly enriched in CD56brightperforinlow cells, and the distribution of NK subsets appeared in accordance with tissue gene expression of chemotactic factors, for which receptors are differently represented in the two subsets. Remarkably, chemokine expression pattern of tissues was modified after neoplastic transformation. As a result, although the total amount of NK cells infiltrating the tissues did not significantly change upon malignant transformation, the relative proportion of NK subsets infiltrating the tissues was different, with a trend toward a tumor-infiltrating NK population enriched in noncytotoxic cells. Besides solid tissues, CD56brightperforinlow NK cells were also detected in seroma fluids, which represents an accrual of human afferent lymph, indicating that they may leave peripheral solid tissues and recirculate to secondary lymphoid organs via lymphatic vessels. Our results provide a comprehensive mapping of NK cells in human tissues, demonstrating that discrete NK subsets populate and recirculate through most human tissues and that organ-specific chemokine expression patterns might affect their distribution. In this context, chemokine switch upon neoplastic transformation might represent a novel mechanism of tumor immune escape.

1 May 2008 in Journal of Hepatology
Verified
Journal Article
Closed access
GRGiovanni Raimondo
Giovanni Raimondo
GNGiuseppe Navarra
Giuseppe Navarra
Stefania MondelloStefania Mondello
Stefania Mondello
LCLucy Costantino
Lucy Costantino
GCGuido Colloredo
Guido Colloredo
TPTeresa Pollicino
Teresa Pollicino

25 February 2015 in Liver International
Verified
Journal Article
Closed access
PDF file
CSCarlo Saitta
Carlo Saitta
GTGianluca Tripodi
Gianluca Tripodi
ABAdalberto Barbera
Adalberto Barbera
ABAntonio Bertuccio
Antonio Bertuccio
ASAntonina Smedile
Antonina Smedile
TPTeresa Pollicino
Teresa Pollicino

1 March 2003 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
PCPaolo Carcoforo
Paolo Carcoforo
GSGiorgio Soliani
Giorgio Soliani
UMUmberto Maestroni
Umberto Maestroni
ADA Donini
A Donini
DIDaniel Inderbitzin
Daniel Inderbitzin
GNGiuseppe Navarra
Giuseppe Navarra
Axillary lymph node dissection for staging and local control of nodal disease is an integral part of breast cancer therapy. Lymphorrea is a serious and disabling complication of axillary lymphadenectomy, but no effective therapy is currently available. Octreotide is a hormone with general antisecretory effects that has been used to control lymphorrhea in thoracic duct injury and after radical neck dissection. The aim of the study we describe in this article was to determine whether octreotide has a role in the treatment of post axillary lymphadenectomy lymphorrhea. This is a prospective randomized controlled trial. Two hundred sixty-one consecutive patients with various stages of breast cancer who underwent axillary lymph node dissection were randomized and followed for 7 years. The treatment group received 0.1 mg octreotide subcutaneously three times a day for 5 days, starting on the first postoperative day, while the control group received no treatment. Of the 261 patients undergoing axillary node dissection, 136 were assigned to the control group and 125 composed the treatment group. The control group and the treatment group were evaluated for amount and duration of lymphorrhea as well as inflammatory and infectious complications. In the control group, the mean quantity (+/- standard deviation) of lymphorrhea was 94.6 +/- 19 cc per day and the average duration was 16.7 +/- 3.0 days. In comparison, the mean quantity of lymphorrhea in the treatment group was 65.4 +/- 21.1 cc (p < 0.0001) per day and the average duration was 7.1 +/- 2.9 days (p < 0.0001). We did not find an important difference in the number of infectious complication or hematomas formation between the study groups. Octreotide can be used successfully for the treatment of post-axillary dissection lymphorrea, and potentially, in the prevention of post-axillary lymph node dissection lymphosarcoma, since the amount and duration of lymphorrhea in this setting are known to be important risk factors for its development. Potentially, octreotide might be used in similar situations where lymphorrhea is detrimental, such as peripheral vascular surgery and regional lymph node dissection for melanoma.

19 April 2015 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
GCGiuseppe Currò
Giuseppe Currò
GMGiuseppe La Malfa
Giuseppe La Malfa
ACAntonio Caizzone
Antonio Caizzone
VRValentina Rampulla
Valentina Rampulla
GNGiuseppe Navarra
Giuseppe Navarra